X-37 is a pharmaceutical discovery and development company, which uses advanced artificial intelligence technology from Atomwise, Inc. to discover novel drug candidates by screening vast libraries of chemical compounds against high-value pharmaceutical targets. X-37 develops these novel drug candidates under an innovative LLC structure that allows simple and efficient sales or partnerships for individual development programs. The team at X-37 possesses extensive expertise in the selection of high-value pharmaceutical targets and pharmaceutical development.
X-37 has initiated five development programs in areas of high medical need including cancer, autoimmune diseases, and coagulation disorders. The team at X-37 will advance drug candidates identified via AtomNet through initial screening assays and pre-clinical testing with a goal to begin human clinical trials in 2022.
Initial funding is from DCVC Bio, Alpha Intelligence Capital, and Hemi Ventures.
The team at X-37 will advance drug candidates identified via AtomNet through initial screening assays and pre-clinical testing with a goal to begin human clinical trials in 2022.
David is the Chief Executive Officer of X-37. He has had a long career in creating and financing new biotechnology companies, primarily focusing on the discovery and development of new pharmaceutical candidates.
As an investor, David has worked as a Managing Director at the San Francisco-based venture capital firm Presidio Partners (www.presidiopartners.com) since 2001. While at Presidio, David made many investments in promising early-stage biotechnology companies. Notable successes include Biomimetic Therapeutics (IPO, then acquired by Wright Medical), Centrexion Therapeutics, Altus Pharmaceuticals (IPO), and Auspex Pharmaceuticals (IPO, then acquired by Teva).
In addition to co-founding X-37, David co-founded Velocity Pharmaceutical Development (www.vpd.net) in 2011 and has led the company as its CEO since then. David played a major role in in-licensing serlopitant from Merck & Co. to create Tigercat Pharma (now Menlo Therapeutics, NASDAQ: MNLO), in the sale of Spitfire Pharma to Altimmune, Inc. (NASDAQ: ALT), and in negotiating the strategic partnership between Corsair Pharma and United Therapeutics.
David currently serves as a member of the board of directors of Exela Pharma Sciences (www.exelapharma.com).
David holds an M.D. from the University of Pennsylvania School of Medicine, an M.B.A. from the Wharton School, and a B.A. in Physics from Wesleyan University.
Matt has significant combined academic and industry bioengineering experience in microfluidics, drug discovery, quantitative modeling and structured data analysis. He holds a Ph.D. in Biomedical Engineering and is licensed in California as a Professional Chemical Engineer (PE). Matthew co-founded two life science companies, Lucidant Polymers and Cytomag at the Panorama Research Institute. He served as co-chairman of the Life Science Angels BIO screening committee for two years and has reviewed hundreds of proposals for funding. He has worked with Velocity Pharmaceutical Development since 2009 searching for and developing pharmaceutical compounds for multiple disease indications.
He earned a B.S. in Chemical Engineering from the University of California, Davis and obtained a M.S. in Biomedical Engineering from CSU Sacramento while working with the UC Davis Medical Center to create a mathematical model to quantitate diabetic severity in humans based on experimental tracer studies. He joined Point Biomedical Corp, a pre-IPO startup, to develop ultrasound contrast agent and formulate encapsulated drug delivery vehicles. These 5 micron-size particles were developed using optical test systems, lasers, microscopes and complex organic emulsions.
In 2000, he moved to Caliper Technologies to develop novel microfluidic tools for screening pharmaceutical inhibitors to human kinase enzymes. He worked with both the fundamental microfluidics group and systems integrations group to design complete assay platforms. He later founded his own consulting company and worked to engineer new fluidic products for cell transfection and pharmaceutical lyophilization.
He joined the Chemical and Biochemical Engineering laboratory of Dr. Anubhav Tripathi, an expert in fluid dynamics, at Brown University for Ph.D. studies. His thesis work integrated quantitative analysis of kinetics, microfluidics, molecular biology and viral diagnostics. The research increased the understanding of molecular conformation and structural influence on the mechanisms of transport, reaction kinetics and thermodynamic properties. He received a Ph.D. from Brown University in Biomedical Engineering.
At Stanford University, he held a joint appointment in the departments of Engineering and Medicine as a Bioengineering Bio-X division postdoctoral scholar then staff. Matthew brought expert knowledge of device design and fabrication to enable several exciting collaborations on human stem cells, cancer cell resistance to therapeutics, next generation DNA sequencing and the properties of innate immune response. He developed integrated fluidic systems for electronic field effect transistor (FET) based diagnostics and tissue encapsulation systems for bone regeneration using adult adipose stem cells. He has published and presented in the fields of microfluidics and biomolecular analysis.
Dr. James Larrick is a biomedical entrepreneur with an international reputation in biotechnology. He has developed expertise in cytokines, therapeutic antibodies, molecular biology, and pharmaceutical drug development over his twenty-five-year career, and he has written or co-authored nine books, published over 300 papers/chapters, and submitted more than fifty patents.
Dr. Larrick earned his M.D. and Ph.D. from Duke University as a graduate of the prestigious Medical Scientist Training Program. After completing his medical house-staff training at Stanford University, Dr. Larrick contributed to the development of the first therapeutic human monoclonal antibodies for cancer and infectious diseases as a postdoctoral research fellow in the Stanford Cancer Biology Research Labs. He built upon this work as a founding scientist of Cetus Immune Research Labs, which he led during the 1980s.
In 1991, Dr. Larrick founded the Panorama Research Institute (PRI), a biopharmaceutical translational organization that he continues to lead today. Dr. Larrick’s PRI team has discovered and initiated the development of a diverse and innovative portfolio of pharmaceutical molecules addressing major unmet needs in cancer, infectious, autoimmune, cardiovascular, neurological and metabolic diseases. PRI has incubated over twenty life science projects/companies, including legacy start-ups: Kalobios Inc., Galaxy Biotechnology Inc., NuGen Technology Inc., Adamas Inc., and Absalus Inc. (now Teva). PRI has also co-founded two companies in Europe: PanGenetics b.v. (Abbvie) and TargetQuest b.v. (Dyax). To date, PRI-initiated projects and/or companies have led to seven IPOs/exits. Recent work at PRI has focused on Applied Healthspan Engineering -- the utilization of advances in molecular medicine to preserve well-being as we age.
Since the late 1990s, Dr. Larrick has served as head of biopharma project-screening for two angel investment groups, TENEX and, more recently, Life Science Angels. In 2011, he co-founded Presidio Partners-funded Velocity Pharmaceutical Development, LLC, where he currently serves as Managing Director and Chief Medical Officer in South San Francisco. Genetic Engineering News (GEN) has recognized Dr. Larrick as a “Top Serial Bio Entrepreneur” over multiple years.
Dr. Larrick has organized and led several biomedical expeditions to study nutrition, malaria, genetics, and high-altitude adaptation among native peoples of Ecuador, Peru, Guatemala, Nepal, India, Tibet, and China. In addition to providing financial support, he also currently serves on the boards of two non-profit organizations, the Sustainable Sciences Institute (www.ssilink.org) and the Sankofa Center for African Dance and Culture (www.thesankofacenter.org), which focus on education and the delivery of appropriate technology to less developed countries in Africa and Latin America and education, diagnosis, and therapy of HIV/AIDS and tuberculosis in Ghana, respectively. He also supports outreach clinics and hospitals in Ethiopia, Komodo Island, and Bhutan (Juvare.org).
Andy has had a notable career in drug development, most significantly at Genentech from 1988 to 1993, where he played a key role in the development, FDA approval, and marketing of human growth hormone (hGH, Nutropin) as Senior Director of Clinical Research. He was also responsible for the development of Genentech's entire portfolio of endocrine drugs and drug candidates. In addition, he also maintained a research lab at Genentech and was a member of the team responsible for the evaluation and selection of new therapeutic drug candidates.
After Genentech, Andy was one of the first hires at Tularik, a new drug discovery company, where he served as Vice President and then Executive Vice President until 2004, except for nine months in 2002 when he served as CEO of Affymax. While at Tularik, Andy's responsibilities included participating in the selection of promising targets for new drugs and compounds for further development. In addition, he was responsible for clinical trial design and implementation, filing Tularik's first IND, and initiating the relevant clinical trials. Later he played an active role in Tularik's business development, investor relations, and financing activities, culminating with Tularik's acquisition by Amgen in 2004 for $1.3 billion.
Following the acquisition of Tularik, Andy was the founder and CEO of Innate Immune Inc., an early-stage biotech company focused on developing therapies for asthma and autoimmune diseases. He also worked with a team at The Palo Alto Research Center to determine the clinical value of a new technique for the identification and enumeration of rare tumor cells in the peripheral circulation. He is an advisor to the venture capital firm 8VC and an advisor to several biotechnology companies.
Andy has a B.S. from MIT, an M.D. and a Ph.D. in physiology from New York University (NYU). He did his Ph.D. research in the laboratory of Nobel laureate Professor Eric Kandel. He received postgraduate clinical training at Stanford School of Medicine and NYU. He worked as a staff scientist at the Medical Research Council in London from 1983 to 1984, continuing his medical research on steroid hormone nuclear receptors. From 1984 to 1987 he was an assistant professor at Stanford University where he did clinical work, teaching and research on hypertension.
Anie is a Life Sciences attorney with significant experience in providing legal support for the development and commercialization of therapeutic programs. She has developed and implemented patent strategies for a wide variety of companies in areas such as protein chemistry, pharmaceutical sciences, pharmacology, neuroscience, bioinformatics, and molecular biology. She was an Adjunct Professor at USF Law School where she taught patent prosecution. She has held Vice President roles at Elixir Medical, Adamas Pharmaceuticals, and Menlo Therapeutics. Previously, she was a Partner in Wilson Sonsini Goodrich & Rosati's intellectual property and patent practice as well as an Associate in the law firm of Cooley Godward LLP.
Anie conducted research in the fields of pharmacology, neuroscience, anatomy, electrophysiology, and biochemistry. For her graduate degree, she researched neurochemical modifications in the central nervous system during inflammation. Anie has also studied the interactions between opioid receptors and pain-transmitting neurons. She has authored several scientific publications and has presented her research at national and international meetings.
Anie received her Bachelor's degree in Pharmaceutical Sciences from the University of Mumbai, her Ph.D. from the University of Minnesota in the fields of Pharmacology and Neuroscience, and her J.D. from the University of Minnesota Law School.
Ed is the Head of Clinical Development at X-37. He has been working in the pharmaceutical industry for several decades and has been involved in the clinical development of many drugs from IND to NDA at both large and small pharmaceutical companies.
Ed has held senior management positions at Hoffmann-LaRoche, Alza, Cellgate, and Novacea, where he managed clinical trials across several therapeutic areas including approvals of drugs such as Roferon A, Vesanoid, Saquinavir, Doxil, Duros Leuprolide, and Concerta.
Ed was also a founding member of Velocity Pharmaceutical Development and helped manage the clinical program for Tigercat Pharma leading to the successful IPO of the company now known as Menlo Therapeutics. He is also involved in the development of a new treatment for pulmonary arterial hypertension at Corsair Pharma.
Ed holds an MD degree from Georgetown University. He completed a fellowship in Hematology at New York University and was an oncology fellow at Memorial – Sloan Kettering Cancer Center.